A novel drug produced by Swiss multinational pharmaceutical company Novartis could prove to be a radical treatment for patients with heart failure. The experimental medicine, currently classified as LCZ696, was found to cut the risk of cardiovascular deaths ...
Facebook
Twitter
Pinterest
Instagram
Google+
YouTube
LinkedIn
RSS